• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

选择接受经动脉化疗栓塞术的肝细胞癌患者的预后替代肾指标。

Selecting a prognostic renal surrogate for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.

机构信息

Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.

出版信息

J Gastroenterol Hepatol. 2012 Oct;27(10):1581-8. doi: 10.1111/j.1440-1746.2012.07151.x.

DOI:10.1111/j.1440-1746.2012.07151.x
PMID:22497632
Abstract

BACKGROUND AND AIM

Renal insufficiency (RI) often coexists with hepatocellular carcinoma (HCC) and predicts a poor outcome in patients receiving transarterial chemoembolization (TACE). The modification of diet in renal disease (MDRD) and chronic kidney disease epidemiology collaboration (CKD-EPI) equations are used to provide estimated glomerular filtration rate (eGFR). This study aimed to determine a prognsotic renal surrogate for outcome prediction in HCC patients receiving TACE.

METHODS

A total of 684 patients with HCC undergoing TACE were retrospectively analyzed. The prognostic ability between the MDRD and CKD-EPI equation was compared by the Akaike information criterion (AIC).

RESULTS

Patients were categorized by eGFR into > 60, 30-60 and < 30 mL/min per 1.73 m(2) (equivalent to CKD stages 1-2, 3, and 4-5, respectively) groups. The eGFR generated by the MDRD equation had a better predictive accuracy by having a lower AIC score (3234.5) compared to the CKD-EPI equation (3236.7). The adjusted risk ratio for patients with eGFR 30-60 mL/min per 1.73 m(2) by the MDRD was 1.313 (P = 0.041) compared with patients with eGFR > 60 mL/min per 1.73 m(2) in the multivariate Cox model. The eGFR defined by the MDRD equation consistently had better prognostic ability when patients were stratified by the Child-Turcotte-Pugh score of 5 and > 5 and Cancer of the Liver Italian Program score 0 to 1 and > 1.

CONCLUSIONS

The eGFR according the MDRD equation may provide better prognostic accuracy than the CKD-EPI equation independent of liver functional reserve and tumor staging, and is a more feasible renal surrogate for outcome prediction in CKD stage 1-3 HCC patients receiving TACE.

摘要

背景与目的

肾功能不全(RI)常与肝细胞癌(HCC)共存,并预测接受经动脉化疗栓塞(TACE)治疗的患者预后不良。改良肾脏病饮食(MDRD)和慢性肾脏病流行病学合作(CKD-EPI)方程用于提供估算肾小球滤过率(eGFR)。本研究旨在确定 TACE 治疗 HCC 患者预后预测的替代肾指标。

方法

回顾性分析 684 例接受 TACE 的 HCC 患者。通过赤池信息量准则(AIC)比较 MDRD 和 CKD-EPI 方程的预后能力。

结果

根据 eGFR 将患者分为>60、30-60 和<30mL/min/1.73m2(分别相当于 CKD 1-2、3 和 4-5 期)组。MDRD 方程生成的 eGFR 通过具有较低的 AIC 评分(3234.5),预测准确性优于 CKD-EPI 方程(3236.7)。MDRD 方程的 eGFR 为 30-60mL/min/1.73m2 的患者的调整风险比为 1.313(P=0.041),与 eGFR>60mL/min/1.73m2 的患者相比。在多变量 Cox 模型中,当患者按 Child-Turcotte-Pugh 评分 5 和>5 和意大利肝癌计划评分 0 至 1 和>1 分层时,MDRD 方程定义的 eGFR 始终具有更好的预后能力。

结论

MDRD 方程的 eGFR 可能比 CKD-EPI 方程提供更好的预后准确性,独立于肝储备功能和肿瘤分期,是 TACE 治疗 CKD 1-3 期 HCC 患者预后预测的更可行的替代肾指标。

相似文献

1
Selecting a prognostic renal surrogate for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.选择接受经动脉化疗栓塞术的肝细胞癌患者的预后替代肾指标。
J Gastroenterol Hepatol. 2012 Oct;27(10):1581-8. doi: 10.1111/j.1440-1746.2012.07151.x.
2
Differential prognostic impact of renal insufficiency on patients with hepatocellular carcinoma: a propensity score analysis and staging strategy.肾功能不全对肝细胞癌患者预后的影响差异:倾向评分分析和分期策略。
J Gastroenterol Hepatol. 2012 Apr;27(4):690-9. doi: 10.1111/j.1440-1746.2011.06886.x.
3
The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EPI-CysC equations?慢性肾脏病流行病学协作组胱抑素 C(CKD-EPI-CysC)方程对有症状多发性骨髓瘤初诊患者的总生存具有独立的预后价值;是否到了从 MDRD 方程转变为 CKD-EPI-CysC 方程的时候?
Eur J Haematol. 2013 Oct;91(4):347-55. doi: 10.1111/ejh.12164. Epub 2013 Aug 17.
4
Predicting outcomes after myocardial infarction by using the Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification of Diet in Renal Disease study equation: results from the Korea Acute Myocardial Infarction Registry.应用慢性肾脏病流行病学合作方程与肾脏病饮食改良研究方程预测心肌梗死后的结局:来自韩国急性心肌梗死注册研究的结果。
Nephrol Dial Transplant. 2012 Oct;27(10):3868-74. doi: 10.1093/ndt/gfs344. Epub 2012 Aug 9.
5
Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction.肝癌伴腹水患者经肝动脉化疗栓塞术后肝功能衰竭:发生率、危险因素及预后预测。
J Clin Gastroenterol. 2011 Jul;45(6):556-62. doi: 10.1097/MCG.0b013e318210ff17.
6
Prognostic accuracy of staging systems in patients with primary liver cancer undergoing transarterial chemoembolization.经动脉化疗栓塞术治疗的原发性肝癌患者分期系统的预后准确性
Hepatogastroenterology. 2013 May;60(123):481-8. doi: 10.5754/hge12003.
7
Pretransplant renal function according to CKD-EPI cystatin C equation is a prognostic factor of death after liver transplantation.移植前根据 CKD-EPI 胱抑素 C 方程估算的肾功能是肝移植后死亡的预后因素。
Liver Int. 2016 Apr;36(4):547-54. doi: 10.1111/liv.12989. Epub 2016 Jan 30.
8
An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma.基于炎症的预后指数预测肝癌经动脉化疗栓塞后的生存优势。
Transl Res. 2012 Aug;160(2):146-52. doi: 10.1016/j.trsl.2012.01.011. Epub 2012 Jan 30.
9
Comparison of the MDRD Study and the CKD-EPI Study equations in evaluating trends of estimated kidney function at population level: findings from the National FINRISK Study.比较 MDRD 研究和 CKD-EPI 研究方程在评估人群水平估算肾功能趋势方面的差异:来自芬兰国家 FINRISK 研究的发现。
Nephrol Dial Transplant. 2012 Aug;27(8):3210-7. doi: 10.1093/ndt/gfs047. Epub 2012 Apr 6.
10
Estimated glomerular filtration rate and prognosis in heart failure: value of the Modification of Diet in Renal Disease Study-4, chronic kidney disease epidemiology collaboration, and cockroft-gault formulas.估算肾小球滤过率与心力衰竭预后:肾脏病饮食改良研究-4、慢性肾脏病流行病学协作研究及 Cockcroft-Gault 公式的价值。
J Am Coll Cardiol. 2012 May 8;59(19):1709-15. doi: 10.1016/j.jacc.2011.11.066.

引用本文的文献

1
Using serum α-fetoprotein for prognostic prediction in patients with hepatocellular carcinoma: what is the most optimal cutoff?使用血清甲胎蛋白对肝细胞癌患者进行预后预测:最适宜的临界值是多少?
PLoS One. 2015 Mar 4;10(3):e0118825. doi: 10.1371/journal.pone.0118825. eCollection 2015.
2
Surgical resection is better than transarterial chemoembolization for hepatocellular carcinoma beyond Milan criteria independent of performance status.对于超出米兰标准的肝细胞癌,无论其体能状态如何,手术切除都优于经动脉化疗栓塞术。
J Gastrointest Surg. 2014 Sep;18(9):1623-31. doi: 10.1007/s11605-014-2546-9. Epub 2014 May 29.
3
Decrypting cryptogenic hepatocellular carcinoma: clinical manifestations, prognostic factors and long-term survival by propensity score model.
解密隐匿性肝细胞癌:临床表现、预后因素及倾向评分模型的长期生存情况
PLoS One. 2014 Feb 24;9(2):e89373. doi: 10.1371/journal.pone.0089373. eCollection 2014.
4
The incidence of contrast-induced nephropathy (CIN) following transarterial chemoembolisation (TACE) in patients with hepatocellular carcinoma (HCC).肝细胞癌(HCC)患者经动脉化疗栓塞术(TACE)后对比剂肾病(CIN)的发生率。
Eur Radiol. 2014 May;24(5):1105-11. doi: 10.1007/s00330-014-3099-8. Epub 2014 Feb 13.
5
Hepatocellular carcinoma in patients with chronic kidney disease.慢性肾脏病患者的肝细胞癌。
World J Gastroenterol. 2013 Apr 28;19(16):2466-72. doi: 10.3748/wjg.v19.i16.2466.